David H. Ilson, MD, PhD, discusses the main takeaway from the data for phase III TAGS trial reported at the 2019 Gastrointestinal Cancers Symposium.
David H. Ilson, MD, PhD, attending physician and professor of medicine at Memorial Sloan Kettering Cancer Center, discusses the main takeaway from the data for the phase III TAGS trial reported at the 2019 Gastrointestinal Cancers Symposium.
Treatment with TAS-102 (trifluridine/tipiracil; FTD/TPI; Lonsurf) modestly improved progression-free survival and overall survival in patients with refractory gastric or gastroesophageal junction (GEJ) cancer. However, Ilson says this is more of a stabilizing drug since there weren’t really any responses.
Quality of life data in the original trial also showed a slow decline in performance status with TAS-102 compared to placebo. Ilson says this will likely be a good option for patients with refractory disease who do not have other treatment options.
See more from this trial.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More
2 Commerce Drive
Cranbury, NJ 08512